← Back to Search

CCR5 Inhibitor

Maraviroc for Kidney Disease

Phase 2
Waitlist Available
Led By Peter Stock, MD, PhD
Research Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time points in year 1 (four time points: weeks 13, 26, 39, 52)
Awards & highlights

Study Summary

This study is evaluating whether a drug called maraviroc may help prevent HIV from being transmitted to organ recipients.

Eligible Conditions
  • Kidney Disease
  • Human Immunodeficiency Virus Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time points in year 1 (four time points: weeks 13, 26, 39, 52)
This trial's timeline: 3 weeks for screening, Varies for treatment, and time points in year 1 (four time points: weeks 13, 26, 39, 52) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cumulative Incidence of Graft Loss, Toxicities ≥ Grade 3 Per the DAIDS Toxicity Table and/or Permanent Treatment Discontinuation
Mean Glomerular Filtration Rate by Iohexol Clearance at Week 52
Secondary outcome measures
AUC of CCR5 Blockade (Maraviroc)
Calcineurin Inhibitor (Tacrolimus) AUC for Participants on Maraviroc Versus Placebo
Calcineurin Inhibitor (Tacrolimus) Trough Levels for Participants on Maraviroc Versus Placebo
+23 more

Side effects data

From 2008 Phase 4 trial • 18 Patients • NCT00666705
6%
Folliculitis
6%
Constipation
6%
Peripheral neurophathy
6%
Somnolence
100%
80%
60%
40%
20%
0%
Study treatment Arm
Maraviroc
Maraviroc + Raltegravir
Raltegravir

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm 1: Maraviroc (MVC)Experimental Treatment1 Intervention
Participants will receive MVC at the time of admission for transplantation and prior to transplant. Participants will receive MVC throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
Group II: Arm 2: PlaceboPlacebo Group1 Intervention
Participants will receive placebo at the time of admission for transplantation and prior to transplant. Participants will receive placebo throughout their participation in the study, which will be 1 to 3 years depending on when they enroll.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Maraviroc
2014
Completed Phase 4
~1770

Find a Location

Who is running the clinical trial?

National Institute of Allergy and Infectious Diseases (NIAID)Lead Sponsor
3,270 Previous Clinical Trials
5,485,140 Total Patients Enrolled
Peter Stock, MD, PhDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
76 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
2017. "Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02741323.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top